Amgen Faces Safety Crisis After 20 Deaths in Japan; U.S. Regulators Seek Withdrawal

Amgen is grappling with a severe drug safety crisis following reports that 20 people in Japan died after taking a rare immune-disease medication. According to reports, U.S. drug regulators have formally requested that the company voluntarily withdraw the drug from the market. Additionally, Kissei Pharmaceutical, the local distributor, has warned Japanese physicians to cease prescribing the treatment to new patients immediately.

These developments emerge as a significant headwind compared to peers like Regeneron and Biogen. Historically, voluntary withdrawals of high-stakes specialty drugs lead to substantial litigation risks and revenue loss, per market data. This safety failure could undermine investor confidence in Amgen's broader R&D pipeline, especially as the biotech sector faces increased regulatory scrutiny following recent earnings cycles.

Investors are closely monitoring Amgen's price action following this news, as market data indicates heightened volatility. Looking ahead, upcoming catalysts include speeches from Fed officials on May 12, 2026, which may influence broader market sentiment for high-growth healthcare stocks. The market remains focused on whether the company will issue a formal financial impact assessment regarding the withdrawal in the coming days.